Sofosbuvir + velpatasvir

Y. Vivian Tsai, Pharm.D., Janessa M. Smith, PharmD, BCPS

INDICATIONS

FDA

  • Treatment of pediatric patients (≥3 years old) and adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 without cirrhosis, or with compensated cirrhosis, or with decompensated cirrhosis in combination with ribavirin

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: September 16, 2026